Please login to the form below

Not currently logged in


This page shows the latest BIO news and features for those working in and with pharma, biotech and healthcare.

Regeneron and Bluebird sign $100m cell therapies deal

Regeneron and Bluebird sign $100m cell therapies deal

Big biotech’Regeneron and cell and gene therapy specialists Bluebird Bio have unveiled a new collaboration which gives both greater presence in next-generation cell therapies. ... The collaboration with Regeneron complements Bluebird Bio’s growing

Latest news

More from news
Approximately 11 fully matching, plus 182 partially matching documents found.

Latest Intelligence

  • Bluebird Bio: on the cusp of a gene therapy revolution Bluebird Bio: on the cusp of a gene therapy revolution

    Bluebird Bio: on the cusp of a gene therapy revolution. Nick Leschly talks to PME about Bluebird's remarkable gene therapy pipeline and why it’s filing first in Europe. ... The next company to play its hand in this biotech-led transformation of

  • The sound of silence puts the squeeze on generics and biosimilars The sound of silence puts the squeeze on generics and biosimilars

    Van den Hoven wants SPCs to hold firm in Europe but with a waiver for generic and bio-similar companies to compete with India, Canada and China - not restricted by SPCs -

  • Deal Watch December 2016 Deal Watch December 2016

    Defymed. Not disclosed. Not disclosed. Bio-artificial pancreas for Type 1 diabetes.

  • Deal Watch October 2016 Deal Watch October 2016

    Another example is DM Bio, a joint venture between Dong A of South Korea and Meiji Seika of Japan who this month signed a deal with Gedeon Richter for a biosimilar

  • Deal Watch September 2016 Deal Watch September 2016

    bio has paid an upfront fee of $15m, milestone payments of $1+ bn plus royalties and R&D funding. ... 1, 695. Medigene /Bluebird bio. Licence. Development and commercialisation of T cell receptor (TCR) immunotherapies against four targets, P1 ready,

More from intelligence
Approximately 0 fully matching, plus 25 partially matching documents found.

Latest appointments

More from appointments
Approximately 4 fully matching, plus 11 partially matching documents found.

Latest from PMHub

  • A4P Bio Consulting Ltd

    A4P Bio Consulting Ltd. As experts in biomarkers, bioanalysis, pharmacokinetics, logistics and quality systems management A4P deliver scientifically robust, regulatory compliant, cost effective and value added solutions for the global life

  • emotive. expands client services team

    Alongside his role at emotive. Rob is currently studying for an MSc in Bio-business at Birkbeck, University of London, with a focus on entrepreneurship in the bio-industry.

  • Cuthbert Simpkins on reducing the bioavailability of nitric oxide to improve patient survival

    Cuthbert Simpkins, President and Chief Innovation Officer at Vivacelle Bio, Inc. ... talks to us about the origin of Vivacelle Bio. He mentions how despite being able to fix physical injury, death can still occur due to an overproduction of nitric oxide,

  • Cello Health BioConsulting Appoints Senior Pharma Marketer As President

    He will drive our expansion, not only working with our growing team of strong consultants as leading advisers to the bio-pharmaceutical and healthcare sector, but also contributing to our overarching

  • The Biosimilar Challenge

    The Biosimilar Challenge. The ‘ biosimilar challenge’ (or ‘ bio battle’) is one of the most significant commercial changes we have seen in the pharma industry.

More from PMHub
Approximately 1 fully matching, plus 26 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Cello Health

Cello Health’s mission is to help our clients unlock the potential that exists with their assets, brands and organisations in...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....